Journal ArticleDOI
Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Ian C. Lawrance,Graham L. Radford-Smith,Graham L. Radford-Smith,Peter A. Bampton,Jane M. Andrews,Pok-Kern Tan,Anthony Croft,Richard B. Gearry,Timothy H. Florin +8 more
Reads0
Chats0
TLDR
The aim of this study was to examine the Australian/New Zealand experience of serious infections and TB in IBD patients receiving anti‐TNF‐α therapy from 1999–2009.Abstract:
Ian C Lawrance, Graham L Radford-Smith, Peter A Bampton, Jane M Andrews, Pok-Kern Tan, Anthony Croft, Richard B Gearry and Timothy H J Florinread more
Citations
More filters
Journal ArticleDOI
Systematic review: macrophage activation syndrome in inflammatory bowel disease
TL;DR: Clinically, macrophage activation syndrome is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25.
Journal ArticleDOI
Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease
Alissa Walsh,Martin Weltman,Daniel Burger,S. Vivekanandarajah,Susan J. Connor,M. Howlett,Graham L. Radford-Smith,Graham L. Radford-Smith,Warwick Selby,A.S. Veillard,Michael Grimm,Simon Travis,Ian C. Lawrance +12 more
TL;DR: Implementation of a screening and vaccination proforma significantly changed gastroenterologist self-reported behaviour and suggests the need for further patient education, in addition to other forms of support.
Journal ArticleDOI
Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
TL;DR: Older patients on corticosteroids, multiple immunosuppressive agents, and patients with lymphopenia should be considered for prophylaxis, as well as other non-HIV cohorts, for PJP infection.
Journal ArticleDOI
Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study.
Shin-Yi Tsai,Shin-Yi Tsai,Tse-Yen Yang,C.-L. Lin,Y.-H. Tsai,Y.-H. Tsai,Chien-Feng Kuo,Chia-Hung Kao +7 more
TL;DR: Whether patients with inflammatory bowel disease exhibit a high risk of developing varicella zoster virus (VZV) infection in Asian populations remains inconclusive, and the causal relationship between two diseases is investigated by analysing the Taiwan National Health Insurance Research Database.
Journal ArticleDOI
A medicinal plant compound, capnoidine, prevents the onset of inflammation in a mouse model of colitis
Catherine Shepherd,Paul R. Giacomin,Severine Navarro,Catherine M. Miller,Alex Loukas,Phurpa Wangchuk +5 more
TL;DR: Capnoidine presents as a potential new anti-inflammatory drug lead candidate for diseases where current standard-of-care often fails and is associated with major side effects and underlines the value of pursuing bioactive compounds derived from traditionally used ethnobotanical medicines.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frederic Colombel,William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Remo Panaccione,Stefan Schreiber,Dan Byczkowski,Ju Li,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Related Papers (5)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier,Fernando Magro,Candida Abreu,Alessandro Armuzzi,Shomron Ben-Horin,Yehuda Chowers,Mario Cottone,L. de Ridder,Glen A. Doherty,Robert Ehehalt,Maria Esteve,K.H. Katsanos,Charlie W. Lees,Eithne MacMahon,Tom G. Moreels,Walter Reinisch,Herbert Tilg,Lydjie Tremblay,Gigi Veereman-Wauters,N. Viget,Yazdan Yazdanpanah,Rami Eliakim,Jean-Frederic Colombel +22 more